Curexsys Appoints Christian Eckert as Chief Operating Officer
Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Ecke…
Curexsys GmbH, a leader in the emerging field of therapeutic exosomes, today announced the appointment of Christian Ecke…
. – Entwicklung oraler Therapien mit Best-in-Class-Potenzial – Führendes Programm, IMU-838, in Phase-2-Studien in Colit…
. – Developing Oral Therapies with Best-in-Class Potential – – Lead Program, IMU-838, Already Advanced into Phase 2 St…
Transaction Expected to Create NASDAQ-listed Biopharmaceutical Company Focused on Advancing Immunic‘s Compelling Pipelin…
. - Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity fina…
. - Omega und Fund+ verstärken Immunic’s Investorenbasis mit einem weiteren Eigenkapital-Investment von EUR 10 Millionen…
Kuros Biosciences gibt bekannt, dass die gestrige Generalversammlung sämtliche Anträge des Verwaltungsrates mit grosser…
. Daniel Vitt verstärkt den Vorstand der Immunic als Chief Executive Officer (CEO) Hella Kohlhof verstärkt den Vorstan…
Two executives with deep understanding of the immunology field, and with experience in the IMU-838/IMU-366 development p…
One of the largest Series A biotech venture capital financings in Germany Venture capital consortium led by renowned sec…